Prague Med. Rep. 2023, 124, 392-412
https://doi.org/10.14712/23362936.2023.30
Polypharmacy and Drug Interactions in the COVID-19 Pandemic
References
1. 2023) Development and implementation of the Hdc.DrApp.la and SIMDA programs to reduce polypharmacy and drug-drug interactions in patients hospitalized in internal medicine. Rev. Recent Clin. Trials 18(2), 156–166.
< , R. E., Keller, G. A., Azzato, F., Diez, R. A., Sielecki, M., Kleine, R. S., Lescano, J. A., Giunti, G. (https://doi.org/10.2174/1574887118666230208124744>
2. 2021) Assessment of the safety and therapeutic benefits of convalescent plasma in COVID-19 treatment: A systematic review and meta-analysis. Front. Med. (Lausanne) 8, 660688.
< , D. F., Lourenço, R. A., Calisto, R., Moreira-Gonçalves, D., Santos, L. L., Videira, P. A. (https://doi.org/10.3389/fmed.2021.660688>
3. 2021) Descriptive analysis of 4776 patients admitted to medical clinic services for COVID-19. Results of the Argentine Multi-Center Registry – REMA-COVID-19. Medicina (B. Aires) 81(5), 703–714. (in Spanish)
, B. R., Mirofsky, M., Valentini, R., Peuchot, V. A., Cámera, L. A., Pollán, J. A., Zylberman, M., Valdez, P.; Grupo de Trabajo COVID-19 (
4. 2020) The effect of age on mortality in patients with COVID-19: A meta-analysis with 611,583 subjects. J. Am. Med. Dir. Assoc. 21(7), 915–918.
< , C., García-Blas, S., Tarazona-Santabalbina, F., Sanchis, J., Bertomeu-González, V., Fácila, L., Ariza, A., Núñez, J., Cordero, A. (https://doi.org/10.1016/j.jamda.2020.05.045>
5. CDC (2019) Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing. Available at: https://www.cdc.gov/coronavirus/2019-ncov/lab/naats.html (last accessed in March 2023)
6. CDC COVID-19 Response Team (2020) Severe outcomes among patients with coronavirus disease 2019 (COVID-19) – United States, February 12-March 16, 2020. MMWR Morb. Mortal. Wkly. Rep. 69(12), 343–346.
7. 2020) Mild or moderate Covid-19. N. Engl. J. Med. 383(18), 1757–1766.
< , R. T., Lynch, J. B., Del Rio, C. (https://doi.org/10.1056/NEJMcp2009249>
8. 2021) A systematic review and a meta-analysis comparing prophylactic and therapeutic low molecular weight heparins for mortality reduction in 32,688 COVID-19 patients. Front. Pharmacol. 12, 698008.
< , R., Menichelli, D., Pani, A., Tratta, E., Romandini, A., Roncato, R., Nani, A., Schenardi, P., Diani, E., Fittipaldo, V. A., Farcomeni, A., Scaglione, F., Pastori, D. (https://doi.org/10.3389/fphar.2021.698008>
9. 2021) Polypharmacy among COVID-19 patients: A systematic review. J. Am. Pharm. Assoc. (2003) 61(5), e14–e25.
< , S., Mgbere, O., Essien, E. J. (https://doi.org/10.1016/j.japh.2021.05.006>
10. 2021) Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: A systematic review and meta-analysis. JAMA 325(12), 1185–1195.
< , P., Axfors, C., Schmitt, A. M., Gloy, V., Ebrahimi, F., Hepprich, M., Smith, E. R., Haber, N. A., Khanna, N., Moher, D., Goodman, S. N., Ioannidis, J. P. A., Hemkens, L. G. (https://doi.org/10.1001/jama.2021.2747>
11. 2009) Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging 26(12), 1039–1048.
< , J., Enlund, H., Korhonen, M. J., Sulkava, R., Hartikainen, S. (https://doi.org/10.2165/11319530-000000000-00000>
12. 2013) Kidney function and clinical recommendations of drug dose adjustment in geriatric patients. BMC Geriatr. 13, 92.
< , M., Schmid, E., Wagenpfeil, S., Linde, K., Heemann, U., Schneider, A. (https://doi.org/10.1186/1471-2318-13-92>
13. 2021) CONVALESCENT plasma for COVID-19: A meta-analysis of clinical trials and real-world evidence. Eur. J. Clin. Invest. 51(11), e13663.
< , C., Saesong, M., Sangsuemoon, J., Chantharit, P., Mongkhon, P. (https://doi.org/10.1111/eci.13663>
14. 2021) Disease-drug and drug-drug interactions in COVID-19: Risk and assessment. Biomed. Pharmacother. 139, 111642.
< , D., Trivedi, N. (https://doi.org/10.1016/j.biopha.2021.111642>
15. 2017) Association between polypharmacy and death: A systematic review and meta-analysis. J. Am. Pharm. Assoc. (2003) 57(6), 729–738.e10.
< , N., Holcombe, A. L., Lund, B. C., Gu, X., Schweizer, M. L. (https://doi.org/10.1016/j.japh.2017.06.002>
16. 2009) A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150(9), 604–612.
< , A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. L., Castro, A. F. 3rd, Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., Coresh, J.; Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) (https://doi.org/10.7326/0003-4819-150-9-200905050-00006>
17. 2021) Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N. Engl. J. Med. 384(7), 610–618.
< , R., Pérez Marc, G., Wappner, D., Coviello, S., Bianchi, A., Braem, V., Esteban, I., Caballero, M. T., Wood, C., Berrueta, M., Rondan, A., Lescano, G., Cruz, P., Ritou, Y., Fernández Viña, V., Álvarez Paggi, D., Esperante, S., Ferreti, A., Ofman, G., Ciganda, Á., Rodriguez, R., Lantos, J., Valentini, R., Itcovici, N., Hintze, A., Oyarvide, M. L., Etchegaray, C., Neira, A., Name, I., Alfonso, J., López Castelo, R., Caruso, G., Rapelius, S., Alvez, F., Etchenique, F., Dimase, F., Alvarez, D., Aranda, S. S., Sánchez Yanotti, C., De Luca, J., Jares Baglivo, S., Laudanno, S., Nowogrodzki, F., Larrea, R., Silveyra, M., Leberzstein, G., Debonis, A., Molinos, J., González, M., Perez, E., Kreplak, N., Pastor Argüello, S., Gibbons, L., Althabe, F., Bergel, E., Polack, F. P.; Fundación INFANT-COVID-19 Group (https://doi.org/10.1056/NEJMoa2033700>
18. 2003) Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study. Thorax 58(5), 377–382.
< , W. S., van der Eerden, M. M., Laing, R., Boersma, W. G., Karalus, N., Town, G. I., Lewis, S. A., Macfarlane, J. T. (https://doi.org/10.1136/thorax.58.5.377>
19. 2020) Analysis of the first 100 patients with COVID-19 admitted to internal medicine wards at the Hospital de Clínicas José de San Martin, Buenos Aires University. Medicina (B. Aires) 80, 48–55 (Suppl. 6). (in Spanish)
, M. G., Labato, M., Chiaradia, V., Yamuni, J., Finocchietto, P., Pisarevsky, A. A. (
20. 2017) What is polypharmacy? A systematic review of definitions. BMC Geriatr. 17(1), 230.
< , N., Shakib, S., Kalisch-Ellett, L., Caughey, G. E. (https://doi.org/10.1186/s12877-017-0621-2>
21. 2020) COVID-19 with and without pneumonia: Clinical outcomes in the internal medicine ward. Medicina (B. Aires) 80, 56–64 (Suppl. 6).
, S. E., Pérez, M. M., Salas, C. E., Haedo, M. F., Xavier, F. B., Saltos Navarrete, J. D., Aguirre, C., Baleta, M. L., Balsano, F. J., Caldano, M. G., Colignon, M. G., de Oliveira Brasil, T., de Wolodimeroff, N., Déramo Aquino, A. I., Fernández de Córdova, A. G., Fontan, M. B., Galvagno, F. I., Iturrieta Araya, N. S., Mollinedo Cruz, V. S., Olivero, A., Pestalardo, I., Ricciardi, M., Vera Rueda, M. L., Villaverde, M. C., Lauko Mauri, M., Ujeda, C., Leis, R. (
22. Ministerio de Salud Argentina (2020a) Tratamiento farmacológico específico con lopinavir/ritonavir de pacientes con infección por COVID. IRETS 2020-03, Informe rápido de evaluación tecnológica sanitaria (IRETS). Available at: https://www.argentina.gob.ar/salud/nuevocoronavirus (last accessed in March 2023)
23. Ministerio de Salud Argentina (2020b) Nuevo coronavirus (COVID-19). Reporte Diario. Available at: https://www.argentina.gob.ar/salud/nuevocoronavirus (last accessed in March 2023)
24. Ministerio de Salud Argentina (2020c) Specific pharmacological treatment with chloroquine in case of COVID-19 infection. IRETS 2020-03b, Informe rápido de evaluación tecnológica sanitaria (IRETS). Available at: https://www.argentina.gob.ar/salud/nuevocoronavirus (last accessed in March 2023)
25. Ministerio de Salud Argentina (2021) Pharmacological treatments evidence. Available at: https://www.argentina.gob.ar/salud/nuevocoronavirus (last accessed in March 2023)
26. 2020) Convalescent plasma for COVID-19: Promising, not proven. Cleve. Clin. J. Med. 87(11), 664–670.
< , S. R., Quraishy, N. (https://doi.org/10.3949/ccjm.87a.ccc056>
27. 2021) Corticosteroids for patients with coronavirus disease 2019 (COVID-19) with different disease severity: A meta-analysis of randomized clinical trials. J. Cardiothorac. Vasc. Anesth. 35(2), 578–584.
< , L., Navalesi, P., Zangrillo, A., Kuzovlev, A., Likhvantsev, V., Hajjar, L. A., Fresilli, S., Lacerda, M. V. G., Landoni, G. (https://doi.org/10.1053/j.jvca.2020.11.057>
28. RECOVERY Collaborative Group; 2021) Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384(8), 693–704.
, P., Lim, W. S., Emberson, J. R., Mafham, M., Bell, J. L., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., Prudon, B., Green, C., Felton, T., Chadwick, D., Rege, K., Fegan, C., Chappell, L. C., Faust, S. N., Jaki, T., Jeffery, K., Montgomery, A., Rowan, K., Juszczak, E., Baillie, J. K., Haynes, R., Landray, M. J. (
29. 2020) Considerations for drug interactions on QTc in exploratory COVID-19 treatment. Circulation 141(24), e906–e907.
< , D. M., Harrington, R. A., Poppas, A., Russo, A. M. (https://doi.org/10.1161/CIRCULATIONAHA.120.047521>
30. 2020) Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun. Rev. 19(7), 102554.
< , M., Rodríguez, Y., Monsalve, D. M., Acosta-Ampudia, Y., Camacho, B., Gallo, J. E., Rojas-Villarraga, A., Ramírez-Santana, C., Díaz-Coronado, J. C., Manrique, R., Mantilla, R. D., Shoenfeld, Y., Anaya, J. M. (https://doi.org/10.1016/j.autrev.2020.102554>
31. 2021) A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N. Engl. J. Med. 384(7), 619–629.
< , V. A., Burgos Pratx, L. D., Scibona, P., Beruto, M. V., Vallone, M. G., Vázquez, C., Savoy, N., Giunta, D. H., Pérez, L. G., Sánchez, M. D. L., Gamarnik, A. V., Ojeda, D. S., Santoro, D. M., Camino, P. J., Antelo, S., Rainero, K., Vidiella, G. P., Miyazaki, E. A., Cornistein, W., Trabadelo, O. A., Ross, F. M., Spotti, M., Funtowicz, G., Scordo, W. E., Losso, M. H., Ferniot, I., Pardo, P. E., Rodriguez, E., Rucci, P., Pasquali, J., Fuentes, N. A., Esperatti, M., Speroni, G. A., Nannini, E. C., Matteaccio, A., Michelangelo, H. G., Follmann, D., Lane, H. C., Belloso, W. H.; PlasmAr Study Group (https://doi.org/10.1056/NEJMoa2031304>
32. 2021) SARS-CoV-2 therapeutics: How far do we stand from a remedy? Pharmacol. Rep. 73(3), 750–768.
< , A., Gupta, V. (https://doi.org/10.1007/s43440-020-00204-0>
33. 2020) Drug repurposing approach to fight COVID-19. Pharmacol. Rep. 72(6), 1479–1508.
< , T. U., Parida, S., Lingaraju, M. C., Kesavan, M., Kumar, D., Singh, R. K. (https://doi.org/10.1007/s43440-020-00155-6>
34. 2020) Corticosteroid use in COVID-19 patients: A systematic review and meta-analysis on clinical outcomes. Crit. Care 24(1), 696.
< , J., Vos, J. S., Hoekstra, E. M., Neumann, K. M. I., Boot, P. C., Arbous, S. M. (https://doi.org/10.1186/s13054-020-03400-9>
35. WHO (2020) Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020. Available at: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (last accessed in March 2023)
36. 2018) DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 46(D1), D1074–D1082.
< , D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., Pon, A., Knox, C., Wilson, M. (https://doi.org/10.1093/nar/gkx1037>